Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aggressive percutaneous transluminal coronary angioplasty (PTCA) as good as stenting:

This article was originally published in Clinica

Executive Summary

Conventional wisdom says stenting may reduce restenosis by scaffolding the coronary artery but new data from the Thoraxcenter in Rotterdam, Holland, suggest that it may simply be a function of larger initial dilation. Dr Patrick Serruys, professor of interventional cardiology and director of the cath lab at the Thoraxcenter, says patients given stent-like PTCA - dilation that reduces stenosis by at least 70% - had similar outcomes to stented patients. However a stent-like result is only achieved in about 35% of PTCA patients compared with 87% of those given stents in the Benestent-I trial (see Clinica No 669/70, p 24). Dr Serruys suggested that trials of provisional stenting should compare results to patients with stent-like PTCA results.

You may also be interested in...

Abbott Readying Vildagliptin ER In India Amid Price Competition

Abbott is developing an extended release version of vildagliptin in India, adding a new dimension to the market dynamics for the DPP-4 inhibitor, which has seen a key patent expire. Sustained release vildagliptin products from Wockhardt and Synokem also appear to be in the works.

AstraZeneca's Risky Lynparza Endpoint In Pancreatic Cancer Goes Before Advisory Cmte.

US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.

Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?

Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts